Most Recent
The High Court has dismissed the ACCC's bid to appeal a Full Federal Court decision upholding a ruling that drug giant Pfizer did not misuse its market power in the months leading up to the expiration of the patent for its blockbuster cholesterol drug Lipitor.
AFT Pharmaceuticals breached the consumer laws with misleading ads over the strength of its painkiller Maxigesic, a judge has found, siding with rival drug maker Reckitt Benckiser.
The Commonwealth of Australia has resolved its claims against pharmaceutical giant Wyeth over the price it paid to list Effexor on the PBS, months after a high stakes trial wrapped up.
Medical device maker American Medical Systems, which is facing a class action over allegedly faulty pelvic mesh implants, has taken a page from the Ethicon pelvic mesh defence playbook, calling on the court to restrict the dates for group membership.
A South Korean biotech company has filed an appeal with the Federal Court after an Ashurst partner succeeded in opposing the company's proposed patent for a genome editing technology.
The Australian Patent Office has thrown out Fisher & Paykel Healthcare's opposition to a patent for a gas supply apparatus used to treat respiratory conditions owned by California-based medical equipment manufacturer, ResMed.
Consumer goods giant Reckitt Benckiser has been permanently barred from displaying select ads for its Strepfen throat lozenges, as the Federal Court dismissed proceedings filed by rival iNova Pharmaceuticals.
A Federal Court judge has expressed her disbelief at a cross claim by generic drug maker Sandoz against Danish multinational H Lundbeck, as the court begins to weigh arguments over damages owed to Lundbeck in the long-running patent case over its blockbuster anti-depressant Lexapro.
Preparations for a December trial between Merck Sharp & Dohme Corporation and Wyeth over four patents for the pneumococcal disease vaccine are underway, and a panel of experts will feature prominently in the high-stakes hearing over the world's best-selling vaccine.
Shareholders in a class action against Sirtex have secured an order forcing the life sciences company to notify them of any plan that would see its $128 million in liquid assets drop below $80 million.